EUVIMEDEUVIMED entdecken
Open Access

Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications

Paul Hsu, Eunice J Choi, Shefali A Patel, William H Wong, Jocelyn G Olvera, Priscilla Yao, Yi Chia Liu, Matthew S Tsai, Wei Wang, Brigid S Boland, John T Chang iD

Inflammatory Bowel Diseases · 03.10.2023 · 29 (10) · 1602-1612

DOI: 10.1093/ibd/izad084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 26.05.2023. Verfasst von Paul Hsu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ulcerative colitis (UC) and Crohn’s disease are 2 types of inflammatory bowel disease (IBD), a group of chronic digestive disorders caused by aberrant immune responses to intestinal microbes. Although changes in the composition of immune cell subsets in the context of IBD have been previously described, the interactions and communication among cells are less well understood. Moreover, the precise mechanisms of action underlying many biologic therapies, including the anti-α4β7 integrin antagonist vedolizumab, remain incompletely understood. Our study aimed to explore possible additional mechanisms through which vedolizumab acts.

Methods

We performed cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) on peripheral blood and colon immune cells derived from patients with ulcerative colitis treated with the anti-α4β7 integrin antagonist vedolizumab. We applied a previously published computational approach, NicheNet, to predict immune cell-cell interactions, revealing putative ligand-receptor pairs and key transcriptional changes downstream of these cell-cell communications (CCC).

Results

We observed decreased proportions of T helper 17 (TH17) cells in UC patients who responded to vedolizumab and therefore focused the study on identifying cell-cell communications and signals of TH17 cells with other immune cells. For example, we observed that colon TH17 cells from vedolizumab nonresponders were predicted to have a greater degree of interactions with classical monocytes compared with responders, whereas colon TH17 cells from vedolizumab responders exhibited more interactions with myeloid dendritic cells compared with nonresponders.

Conclusions

Overall, our results indicate that efforts to elucidate cell-cell communications among immune and nonimmune cell types may increase the mechanistic understanding of current and investigational therapies for IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeInflammatory Bowel DiseasesHumansIntegrinsCell CommunicationGastrointestinal AgentsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

T cellscell-cell communicationssingle-cell RNA-sequencingulcerative colitisvedolizumab

Substanzen

IntegrinsGastrointestinal AgentsvedolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA.
  • Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA.
  • Department of Medicine, Jennifer Moreno Department of Veteran Affairs Medical Center, San Diego, CA, 92161, USA.

ORCID-Profile: John T Chang

Förderung

  • NIDDK NIH HHS
  • NIAMS NIH HHS
  • NIH HHS
  • NIAID NIH HHS
  • CSRD VA
  • BLRD VA
  • NCI NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Hsu, P., Choi, E. J., Patel, S. A., Wong, W. H., Olvera, J. G., Yao, P., Liu, Y. C., Tsai, M. S., Wang, W., Boland, B. S., & Chang, J. T. (2023). Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications. Inflammatory Bowel Diseases, 29(10), 1602-1612. https://doi.org/10.1093/ibd/izad084

Vancouver

Hsu P, Choi EJ, Patel SA, Wong WH, Olvera JG, Yao P, et al. Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications. Inflammatory Bowel Diseases. 2023;29(10):1602-1612. doi:10.1093/ibd/izad084

BibTeX
@article{Hsu2023,
  author = {Hsu, Paul and Choi, Eunice J and Patel, Shefali A and Wong, William H and Olvera, Jocelyn G and Yao, Priscilla and Liu, Yi Chia and Tsai, Matthew S and Wang, Wei and Boland, Brigid S and Chang, John T},
  title = {Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  volume = {29},
  number = {10},
  pages = {1602--1612},
  doi = {10.1093/ibd/izad084}
}
Kostenlos starten →